Highest-materiality recent filing
TruBridge to be acquired by IKS Health for $26.25/share in cash
Per share cash consideration of $26.25; support agreements cover ~27% of outstanding TruBridge common stock.
TruBridge Q4 revenue $87.2M, full-year GAAP net income $4.4M; engages strategic review
Q4 revenue $87.2M (down 1% YoY); bookings $19.8M (+38% YoY); recurring revenue 94%.
TruBridge appoints Pinetree President Damien Leonard to board; three directors to retire by 2027
Damien Leonard (Pinetree President) joins TruBridge Board Jan 12; board expands to 10, then shrinks to 7 after 2026 annual meeting.
Revolver capacity increased to $180M (from $160M); term loan outstanding now $70M (up from $54M).
TruBridge Q3 2025: Revenue $86.1M, GAAP net income $5.6M, Adj EBITDA $16.3M, raises guidance
Total revenue $86.1M, up 1.7% YoY; recurring revenue 94% of total; Financial Health segment $54.5M (63% of revenue).
TruBridge: CSO Dawn Severance to depart Oct 31; Michael Daughton hired as Chief Business Officer
CSO Dawn Severance will leave Oct 31, 2025; position eliminated; no disagreement cited.
Total revenue $85.7M flat YoY; recurring revenue 95%. Financial Health segment $54.3M.
TruBridge dismisses Grant Thornton, appoints KPMG; prior adverse internal control opinions
Audit Committee dismissed Grant Thornton LLP as auditor, effective June 25, 2025.
TruBridge Q1 beats with $87.2M revenue & $18.2M adj. EBITDA; raises FY outlook
Revenue of $87.2M grew 3.7% YoY; GAAP net income $0.5M vs. $1.9M loss; non-GAAP net income $5.2M vs. $3.4M.
TruBridge reports FY2024 revenue $339.2M, net loss $23.1M; issues FY2025 guidance
Q4 2024 revenue $87.4M (up 1.7% YoY); adjusted EBITDA $17.2M vs $12.0M YoY.
TruBridge adds two directors, declassifies board in cooperation deal with top investors
Appointed Jerry Canada (former Group President, Harris Computer Healthcare) and Dris Upitis (Head of Ocho) as independent Class II directors, increasing board from 7 to 9.
TruBridge Q3 revenue $83.8M, bookings $21M; COO David Dye retiring
Q3 revenue $83.8M vs $82.7M YoY; bookings $21.0M (up 40% from $15.0M).
TruBridge Q2 revenue flat at $84.7M, adjusted EBITDA up to $12.6M, reaffirms FY guidance
Total revenue $84.7M vs $84.6M; RCM revenue grew 13% to $54.1M (63.9% of total).
TruBridge Q1: GAAP loss of $0.17/share; FY2024 revenue guidance lowered
Total revenue $83.2M (-3.5% YoY); RCM revenue grew to $53.0M (63.7% of total).
TruBridge amends poison pill, raises triggering threshold to 15% from 10% after stockholder input
Board approved amendment to Rights Plan increasing beneficial ownership threshold from 10% to 15%.
On November 7, 2024, TruBridge, Inc. (the “Company”) announced that David A. Dye will no longer serve as the Company’s Chief Operating Officer, effective December 31, 2024.
On November 1, 2024, TruBridge, Inc. (the “Company”) and David A. Dye, the Company’s Chief Operating Officer and a director of the Company, agreed that Mr. Dye will no longer serve as the Company’s Chief Operating Officer, effective December 31, 2024.
On October 18, 2024, Denise W. Warren submitted her resignation from the Board of Directors (the “Board”) of TruBridge, Inc. (the “Company”), effective November 15, 2024.
Also on October 18, 2024, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board elected Amy O’Keefe, effective immediately, to fill the seat on the Board that will be vacated by Ms. Warren.
Max materiality 1.00 · Median 0.65 · Most common event earnings